

Xintela publishes positive preclinical results from XSTEM treatment of ARDS

Results from Xintela's preclinical study with XSTEM® for the treatment of ARDS (Acute Respiratory Distress Syndrome) have been published in the journal Respiratory Research. The results show that XSTEM has a therapeutic effect and provides more stable blood circulation, reduced lung tissue damage and reduced blood clotting compared to placebo.

Xintela has previously announced that the company's stem cell product XSTEM was evaluated for the treatment of ARDS in a validated preclinical pig model that is clinically similar to the life-threatening lung complication in ARDS patients. The study, which was partly financed by Vinnova, was carried out in collaboration with Professor Sandra Lindstedt and her team at the Department of Thoracic Surgery, Skåne University Hospital in Lund. The results of this study have now been published in the international scientific journal Respiratory Research (<https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-023-02459-6>). The results show, among other things, that the animals treated with XSTEM have more stable blood circulation, less lung tissue damage and lower blood coagulation compared to the animals treated with placebo. No negative side effects were noted during the treatment.

ARDS is a form of acute severe lung failure that can occur as a result of, for example, pneumonia, sepsis or trauma. With this condition, the lung function collapses and the mortality is high. There is no effective treatment available.

“We are really pleased that the results from the study have now been reviewed and published in a very impactful journal. This means that XSTEM will get extra attention as a new treatment option for ARDS with the potential to improve the severe condition in ARDS patients, which can shorten intensive care time and reduce mortality. The results, showing both safety and efficacy, also provide strong support for continued clinical development”, says Xintela's CEO Evy Lundgren-Åkerlund.

Contacts

Xintela AB (publ)

Evvy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evvy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB.

Attachments

[Xintela publishes positive preclinical results from XSTEM treatment of ARDS](#)